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Comprehensive characterization of genomic aberrations in
gangliogliomas by CGH, array-based CGH and interphase FISH
Abstract
Gangliogliomas are generally benign neuroepithelial tumors composed of dysplastic neuronal and
neoplastic glial elements. We screened 61 gangliogliomas [World Health Organization (WHO) grade I]
for genomic alterations by chromosomal and array-based comparative genomic hybridization (CGH).
Aberrations were detected in 66% of gangliogliomas (mean +/- SEM = 2.5 +/- 0.5 alterations/tumor).
Frequent gains were on chromosomes 7 (21%), 5 (16%), 8 (13%), 12 (12%); frequent losses on 22q
(16%), 9 (10%), 10 (8%). Recurrent partial imbalances comprised the minimal overlapping regions
dim(10)(q25) and enh(12)(q13.3-q14.1). Unsupervised cluster analysis of genomic profiles detected two
major subgroups (group I: complete gain of 7 and additional gains of 5, 8 or 12; group II: no major
recurring imbalances, mainly losses). A comparison with low-grade gliomas (astrocytomas WHO grade
II) showed chromosome 5 gain to be significantly more frequent in gangliogliomas. Interphase
fluorescence in situ hybridization (FISH) identified the aberrations to be contained in a subpopulation of
glial but not in neuronal cells. Two gangliogliomas and their anaplastic recurrences (WHO grade III)
were analyzed. Losses of CDKN2A/B and DMBT1 or a gain/amplification of CDK4 found in the
anaplastic tumors were already present in the respective gangliogliomas by array CGH and interphase
FISH. In summary, genomic profiling in a large series of gangliogliomas could distinguish genetic
subgroups even in this low-grade tumor.
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ABSTRACT
Gangliogliomas are generally benign neuroepithelial tumors composed of dysplastic neuronal 
and neoplastic glial elements. We screened 61 gangliogliomas (WHO grade I) for genomic 
alterations by chromosomal and array-based comparative genomic hybridization (CGH). 
Aberrations were detected in 66% of gangliogliomas (2.5±0.5 (mean±SEM) 
alterations/tumor). Frequent gains were on chromosomes 7 (21%), 5 (16%), 8 (13%), 12 
(12%); frequent losses on 22q (16%), 9 (10%), 10 (8%). Recurrent partial imbalances 
comprised the minimal overlapping regions dim(10)(q25) and enh(12)(q13.3-q14.1). 
Unsupervised cluster analysis of genomic profiles detected two major subgroups (group I: 
complete gain of 7 and additional gains of 5, 8, or 12; group II: no major recurring 
imbalances, mainly losses). A comparison with low-grade gliomas (astrocytomas WHO grade 
II) showed chromosome 5 gain to be significantly more frequent in gangliogliomas. 
Interphase-FISH identified the aberrations to be contained in a subpopulation of glial but not 
in neuronal cells. Two gangliogliomas and their anaplastic recurrences (WHO grade III) were 
analyzed. Losses of CDKN2A/B and DMBT1 or a gain/amplification of CDK4 found in the 
anaplastic tumors were already present in the respective gangliogliomas by array-CGH and 
interphase-FISH. In summary, genomic profiling in a large series of gangliogliomas could 
distinguish genetic subgroups even in this low-grade tumor. 
Key words: Gangliogliomas, comparative genomic hybridization, array-based CGH, DNA-
microarray, tumor genetics
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INTRODUCTION
Gangliogliomas are slowly growing, well differentiated neuroepithelial tumors, which may 
occur throughout the central nervous system, but mostly involve the temporal lobe (27). They 
are generally benign and usually correspond to grade I according to the classification of the 
World Health Organization (WHO). Very rarely, gangliogliomas with anaplastic features are 
found and considered to be WHO grade III. Morphologically, these tumors consist of two 
cellular components of dysplastic neuronal and neoplastic glial elements. Accordingly, 
immunostains have demonstrated both neuronal features such as expression of synaptophysin, 
and glial components by staining for GFAP in gangliogliomas (6, 8). In addition, 
approximately 75% of tumors were found to exhibit immunoreactivity for the stem cell 
epitope CD34 (7). Clinically, gangliogliomas are the most common tumors associated with 
chronic temporal lobe epilepsy (6, 8). 
Very little is known about the molecular pathogenesis of gangliogliomas. Few 
gangliogliomas have been analyzed cytogenetically indicating involvement of chromosome 7 
in numerical or structural aberrations as the only alteration detected in more than two cases 
(18, 19, 23, 30, 40). Gain on chromosome 7 was also found recurrently by chromosomal 
comparative genomic hybridization (CGH) analysis of less than 10 cases performed to date 
(31, 38, 46). Certain genes with relevance in other brain tumor entities (e.g. TP53, EGFR, 
PTEN) were not shown to play a substantial role in the pathogenesis of gangliogliomas (11, 
39). There was also no evidence for mutations in genes of the reelin pathway (e.g. CDK5, 
DCX, CDK5R1, DAB1), a major signal transduction cascade in neuronal development and 
cellular migration, in these tumors (4, 22). However, gangliogliomas did show lower mRNA 
expression of these genes compared to normal central nervous system tissue controls (4, 22). 
A number of sequence polymorphisms in the TSC2 gene, a member of the PI3K signaling 
pathway, were found to be significantly more frequent in gangliogliomas than in 
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constitutional DNA from normal individuals suggesting a role for these sequence alterations 
in the molecular pathogenesis of these tumors (5). 
To date, no particular genetic alteration has emerged from these studies to be consistently 
and typically associated with gangliogliomas. Thus, it was the aim of our study to do a 
genome-wide screen for genomic aberrations in a large series of 61 gangliogliomas by 
chromosomal (10, 20) and array-based (32, 37) comparative genomic hybridization (CGH). 
An unsupervised cluster analysis of the results was performed to investigate whether 
gangliogliomas could be subclassified on the basis of their genomic profiles. Since the glial 
cells in gangliogliomas are highly similar to the cells in diffuse astrocytomas 
histopathologically, the imbalances in gangliogliomas were compared with those in 
astrocytomas of WHO grade II. To address the question which of the components carried the 
aberrations found by array-CGH, interphase fluorescence in situ hybridization (FISH) to 
tumor tissue sections was performed with a separate evaluation of glial and neuronal cells. 
Finally, two primary gangliogliomas and their anaplastic recurrences were analyzed by array-
CGH and interphase-FISH to identify genetic aberrations correlated with tumor recurrence 
and set the stage for individualizing therapeutic strategies used for gangliogliomas.
MATERIALS AND METHODS
Tumor samples. CGH analyses were performed on sporadic gangliogliomas from 61 
patients (27 female, 34 male; mean age at operation: 27.9 years; Table 1). In the 51 patients 
with long standing epilepsy, presurgical evaluation had been performed before operation 
within the epilepsy surgery program of the Department of Neurosurgery, Rheinische 
Friedrich-Wilhelms-University, Bonn (9). Informed, written consent was obtained from all 
patients with respect to the use of ganglioglioma tissue for additional studies. All procedures 
were conducted in accordance with the Declaration of Helsinki and approved by the Ethics 
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Committee of the University of Bonn Medical Center. Tumors were reviewed by the same 
neuropathologist and classified as WHO grade I according to the guidelines of the World 
Health Organization (WHO) (25). From 41 tumors, formalin-fixed paraffin-embedded tissue 
samples were analyzed. Unfixed frozen samples were available from 20 tumors. All 
gangliogliomas were investigated for the CD34 epitope status and showed positive staining 
with CD34 antibody. The proportion of neuronal cells was under 10% in all gangliogliomas 
analyzed.
Two gangliogliomas (WHO grade I) from male patients recurred as anaplastic 
gangliogliomas (WHO grade III), also classified according to the WHO guidelines by the 
same neuropathologist (25). Frozen unfixed material was available from both anaplastic 
gangliogliomas. The patients had been treated by surgical resection and had not received 
adjuvant therapy for the primary gangliogliomas.
Nucleic acid extraction. DNA was extracted from paraffin-embedded tissue sections 
of 41 gangliogliomas, and frozen tissue sections of 20 gangliogliomas and two anaplastic 
gangliogliomas (10 sections, 10µm each) by DNeasy Tissue Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions. Care was taken to use only ganglioglioma tissue 
and avoid adjacent normal cortex and white matter. Characteristic neuropathologic features of 
gangliogliomas such as highly differentiated neoplastic glial cell components could be clearly 
determined by microscopic analysis and distinguished from normal central nervous tissue 
components.
As reference DNA for CGH analyses, DNA was extracted from peripheral blood 
lymphocytes of normal individuals according to standard procedures (36).
Chromosomal comparative genomic hybridization (CGH). Metaphase spreads 
were prepared from stimulated peripheral blood lymphocytes obtained from a healthy male 
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subject (46,XY) following standard procedures. CGH was performed with tumor and control 
DNA as described in detail elsewhere (41, 44). For image capture and processing of CGH 
data, the Leica CW4000 System (Leica, Wetzlar, Germany) was used. The diagnostic 
thresholds used to score losses, gains and high-level amplifications were 0.8, 1.2, and 2.0, 
respectively.
Array-based CGH. Twenty gangliogliomas and two anaplastic gangliogliomas, for 
which high molecular weight DNA could be extracted from frozen tumor samples, were 
analyzed by array-CGH using genomic DNA microarrays with more than 6000 large insert 
clones (6k array, 8 tumors), or more than 8000 large insert clones (8k array, 12 tumors). Both 
arrays contained the Sanger Centre 1Mb clone set covering the genome at an average 
resolution of ~1Mb (13). On the 6k array, there were 3000 additional gene- and region-
specific RCPI (RZPD, Berlin, Germany) and CalTech (Invitrogen, Karlsruhe, Germany) BAC 
clones, reaching an average resolution of 0.5Mb (48). The 8k array contained 2000 additional 
clones providing tiling-path resolution of the large GC and gene rich regions on chromosomes 
1, 19 and 22. Array assembly, hybridization and analysis were essentially performed as 
described previously (12, 48), with minor modifications. Hybridization of 6k arrays was 
performed as “dye-swap”. 8k arrays were hybridized with Cy3-labeled tumor DNA and Cy5-
labeled reference DNA. Reference DNA pools were generated from 10 healthy women and 
from 10 healthy men. Hybridizations of all gangliogliomas were sex matched. Array-CGH 
data was processed using the ChipYard framework (URL: 
http://www.dkfz.de/genetics/ChipYard/); for tumor aberrations in cell subpopulations, the 
integrated GLAD-algorithm (16) was used. 
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Interphase fluorescence in situ hybridization (FISH) to tumor tissue sections. 
Interphase-FISH was performed on ganglioglioma no. 46, on the two gangliogliomas with 
malignant recurrences (no. 60 and 61), and on their respective anaplastic gangliogliomas.
Formalin-fixed paraffin-embedded tissue sections of 6µm thickness were deparaffinated. 
Pretreatment and fixation of the slides was performed with the Paraffin Pretreatment Reagent 
Kit 1 (Abbott Vysis, Downer’s Grove, UK) according to manufacturer’s instructions. 
Commercial FISH probes were hybridized according to manufacturer’s instructions. Non-
commercial BAC or PAC clones were labeled with digoxigenin-11-dUTP or biotin-16-dUTP 
(Roche, Basel, Switzerland) by nick translation. FISH was carried out as described previously 
(24). In ganglioglioma no. 46, glial and neuronal cells were distinguished on the basis of their 
nucleus size as determined by staining with the DNA-intercalating fluorophore DAPI. In this 
tumor, such a distinction was possible because of clear differences in size and shape between 
nuclei from glial and neuronal elements as well as ascertained by serial H&E-stained sections. 
Evaluation of FISH analysis was performed in tissue areas found to contain approximately 
80% or more of neoplastic glial and dysplastic neuronal cells selected by H&E staining on 
consecutive sections.
CGH data analysis. CGH annotations conforming to the ISCN 1995 standard (29)
were processed by dedicated software implemented in the Perl scripting language using 
complex Regular Expression based parsing algorithms (1). Data matrices were generated, 
containing the imbalance status (“1” = gain, “-1” = loss, “2” = high level gain) for each of 862 
chromosomal bands. From this data matrix, the frequency of occurrence of gains and losses 
for each interval was determined and histograms were generated. For evaluation of divergent 
imbalance patterns, unsupervised cluster analyses were performed on a reduced density 
matrix (86 intervals) using the Bioconductor "Heatplus" package 
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(http://www.bioconductor.org/). Online versions of the data conversion and visualization 
applications are available through the Progenetix project (2) (http://www.progenetix.net).
Statistical analysis. Comparisons between groups were performed by Fisher’s Exact 
Test, t-test or Mann-Whitney Rank Sum Test, as appropriate. A p-value of <0.05 was 
considered statistically significant.
RESULTS
Genomic imbalances detected by chromosomal or array-CGH. Genomic 
aberrations were detected by CGH in 40 of 61 (66%) gangliogliomas (Table 1, Figure 1) with 
an average of 2.52 ± 0.50 (mean ± SEM) alterations per tumor (range: 0-24). Tumors from 
patients with long standing epilepsy (n = 51) had a significantly lower number of imbalances 
per case than tumors from patients without epilepsy (n = 10) (mean ± SEM: 2.08 ± 0.42 
versus 4.80 ± 2.18; p = 0.02). 
Recurrent gains were identified on chromosomes 7 (21% of tumors), 5 (16%), 8 (13%), 12 
(12%), 19 and X (10% each), Y (9% of tumors from male patients), 20 and 21q (8% each), 19 
(7%), 17 and 6 (5% each), and 3, 4, 9, 10, 11, 13q, 15q, 16 and 18 (3% each). Recurrent 
losses were found on chromosomes 22q (16%), Y (12% of tumors from male patients), 9 
(10%), 10 (8%), 13q, 16, 17 and 18 (7% each), 20 and 21q (5% each) as well as 1, 2, 11, 14q, 
15q and 19 (3% each). 
Recurrent partial losses and gains were found on chromosomes 10 (4 cases) and 12 (2 
cases) (Figure 2). These were losses of 10q22-q26 and 10q25-q26 detected by CGH, as well 
as of 10q21.1-q26.3 and 10q22.3-q25.3 detected by array-CGH, with a minimal overlapping 
region of loss in chromosomal band 10q25. The partial gains on chromosome 12 were 
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mapped to 12p13-q21 (CGH) and 12q13.3-q14.1 (array-CGH: approximately 2 Mb from 
clone RP11-121C6 to RP11-652N17). Small non-recurrent alterations detected by array-CGH 
were a gain of approximately 3.2 Mb in 3p26.2-p26.3 (comprising clones PAC1186B18, 
RP11-306H5, RP11-86C13, RP11-97C16) and a gain of approximately 2.4 Mb in 14q32.13-
q32.2 (comprising clones RP11-298I23 and RP11-164H13).
The genomic profile allows a separation into two ganglioglioma subgroups. 
By unsupervised cluster analysis of gangliogliomas with CGH imbalances, a separation of 
cases into two major subgroups is apparent (Figure 3 A). Group I (Figure 3 A, yellow) is 
defined by a complete gain of chromosome 7. This aberration appears to be related to a 
variety of additional chromosomal gains, i.e. of chromosomes 5, 8, 12, and 19. Gain of 7 can 
also be found in one highly aberrant ganglioglioma not assigned to the two main clusters. 
Group II (Figure 3 A, blue) does not exhibit major recurring imbalances, with the exception of 
losses on chromosomes 9 and 22q, which are, however, not exclusive to this group.
Patients from cluster groups I and II did not differ significantly in age (p = 0.49) or gender 
(p = 0.38). 
Comparison between the genomic aberration pattern of gangliogliomas and 
diffuse astrocytomas. Genomic imbalances in gangliogliomas and 19 diffuse astrocytomas 
of WHO grade II, which were reported by us previously (42, 43), were compared (Figure 3 
B). While the majority of gains and losses in gangliogliomas involved whole chromosomes, 
most imbalances in diffuse astrocytomas involved only parts of chromosomes. The most 
striking difference was gain on chromosome 5, which was found significantly more frequently 
in gangliogliomas than in diffuse astrocytomas (p = 0.05).
Unsupervised cluster analysis of both tumor entities shows that only one diffuse 
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astrocytoma is part of ganglioglioma group I exhibiting a concordant pattern of genomic 
imbalances (Figure 3 C, left part of the heat map). The other diffuse astrocytomas form small 
subclusters defined through single regional aberrations (e.g. gains on 7q) within 
ganglioglioma group II (Figure 3 C, right part of the heat map).
A subpopulation of glial cells carries the chromosomal imbalances. By array-
CGH, losses of chromosome 9, 13q and 22q were found in ganglioglioma no. 46 (Figure 4 A). 
To investigate which tumor cells carried these losses, we used clones from chromosomes 9 
and 22 as probes for interphase-FISH to sections from this tumor. One signal, i.e. a deletion, 
for BAC RP11-392G7 (9q22.32) was detected in 52% of glial cells, whereas no deletion was 
observed in neuronal cells (Figure 4 A). The same was true for BAC CTA-229A8 (22q13), 
which was deleted in 38% of glial cells, but not in any neuronal cell. The control probes 
(RP11-242D8 from 17q21.31 and RP11-279K24 from 4q35.1) showed two signals, i.e. no 
deletion, in the cells analyzed. Thus, a subpopulation of neoplastic glial cells was found to 
contain the chromosomal imbalances, whereas in the dysplastic neuronal cells no aberrations 
were found.
Array-CGH and interphase-FISH results in two gangliogliomas and their 
anaplastic recurrences. Two of the gangliogliomas (WHO grade I) analyzed had recurred 
as anaplastic gangliogliomas (WHO grade III). By array-CGH, one anaplastic ganglioglioma
showed various gains and losses as well as amplifications of chromosomal bands 4q12 and 
12q13.3-q14.1 harboring the genes PDGFRA and CDK4 (Figure 4 B, lower panel, left). By 
interphase-FISH, both amplifications were detected in every tumor cell analyzed. FISH-
probes for PDGFRA (RP11-231C18, 4q12) and CDK4 (RP11-571M6, 12q14.1) showed at
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least 20 signals, whereas a centromere 9 control probe (CEN 9) showed three or four signals 
in all cells indicating a near tri- or tetraploid karyotype (Figure 4 B, lower panel, right). 
In the respective primary ganglioglioma, a gain of 12q13.3-q14.1 including the CDK4
locus was already detectable by array-CGH, while the other aberrations were not found 
(Figure 4 B, upper panel, left). This circumscribed gain of 12q13.3-q14.1 was not found in 
any other ganglioglioma of our series. To investigate copy numbers of CDK4 compared to
PDGFRA showing no gain on a cellular level, we performed interphase-FISH with the same 
probes used in the anaplastic ganglioglioma (Figure 4 B, upper panel, right). Two signals each 
were found for RP11-231C18 (PDGFRA) and CEN9 in 25 of 30 cells. In these 25 cells, nine 
showed two signals for the CDK4 probe (RP11-571M6), seven showed three signals, another 
seven showed four signals, and two cells showed six or seven signals. In five of 30 cells, the 
number of signals for all tested probes was higher than two. Thus in 21 of 30 cells (70%), 
CDK4 was present in more than two copies, but never in over 7 copies.
The other anaplastic ganglioglioma also had multiple aberrations including pronounced 
losses of clones from chromosomal bands 9p21.3 and 10q26.13 harboring the genes 
CDKN2A/CDKN2B and DMBT1 (Figure 4 C, lower panel, left). Interphase-FISH to tissue-
sections of this anaplastic ganglioglioma with probe RP11-149I2 (CDKN2A/B, 9p21.3) and 
control probe RP11-3J11 (9q31.3) with a balanced ratio in array-CGH showed different 
cellular clones (Figure 4 C, lower panel, right). In a total of 49 analyzed cells, the average 
number of signals was 3.36 for RP11-3J11 and 1.73 for RP11-149I2 (CDKN2A/B). In the 
majority of cells (31 of 49), four signals were detected for RP11-3J11; 23 of these had two 
signals and eight one signal for RP11-149I2 (CDKN2A/B). Fifteen cells had three signals for 
RP11-3J11; two of these had three signals, seven had two signals, and six had one signal for 
RP11-149I2 (CDKN2A/B). In addition, interphase-FISH was done with probes for DMBT1
(RP11-481L19, 10q26.13) and control probe RP11-264C14 (10p14) with a balanced ratio in 
array-CGH (Figure 4 C, lower panel, right). In 63 analyzed cells, the average signal number 
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was 3.43 for clone RP11-264C14 and 1.81 for clone RP11-481L19 (DMBT1). In 18 of 63 
cells, two signals were found for each probe. Fourteen cells showed three signals for RP11-
264C14; eight of these had two signals, and six had one signal for RP11-481L19 (DMBT1). In 
18 cells, four signals were found for RP11-264C14; 12 of these had two copies and six one 
copy of RP11-481L19 (DMBT1). In 12 cells, five signals were detected for RP11-264C14; ten 
of these had two signals and two one signal for RP11-481L19 (DMBT1). 
In the array-CGH profile of the respective primary ganglioglioma, losses of clones RP11-
149I2 (CDKN2A/B) and RP11-481L19 (DMBT1) were less pronounced than in the anaplastic 
ganglioglioma but detectable (Figure 4 C, upper panel, left). There was no ganglioglioma in 
our series with a lower ratio for RP11-481L19 (DMBT1), and no other ganglioglioma with a 
combined loss of RP11-149I2 (CDKN2A/B) and RP11-481L19 (DMBT1). By interphase-
FISH, the average number of signals was 2.9 for the control probe (RP11-3J11, 9q31.3) and 
1.94 for RP11-149I2 (CDKN2A/B) in 50 cells analyzed (Figure 4 C, upper panel, right). 
Eleven cells were found with two signals and four cells with three signals for each probe. Five 
cells had two signals for RP11-3J11 and one signal for RP11-149I2 (CDKN2A/B), 17 cells 
had a pattern of three vs. two, and two cells with a pattern of three vs. one signal. In one cell, 
we identified four vs. three signals, in nine cells four vs. two signals, in one cell four vs. one 
signal. By interphase-FISH with other probes, 21 cells were successfully analyzed showing an 
average signal number of 2.67 for control clone RP11-264C14 (10p14) and 1.62 for clone 
RP11-481L19 containing the DMBT1 gene (Figure 4 C, upper panel, right). In five of 21 
cells, two copies were found for each probe. Four cells showed two signals for RP11-264C14 
and one signal for RP11-481L19 (DMBT1). In 10 cells, three signals were detected for RP11-
264C14; one of these had three signals, four had two signals, and five had one signal for 
RP11-481L19 (DMBT1). Two cells showed a signal pattern of four signals for RP11-264C14 
and two signals for RP11-481L19 (DMBT1).
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DISCUSSION
As very little is known about the molecular pathogenesis of gangliogliomas, we used global 
genomic screening methods, i.e. chromosomal and array-based CGH, to comprehensively 
determine the genomic profile in a large series of 61 gangliogliomas. CGH analysis showed 
that the majority of gangliogliomas (66%) carried genomic imbalances mostly involving 
whole chromosomes with a mean number of aberrations of 2.5 per tumor. Interestingly, 
gangliogliomas from patients with long standing epilepsy had a significantly lower median 
number of imbalances per case than tumors from patients without epilepsy. There may be an 
association between these results and the observation that ganglioglioma patients with long 
standing epilepsy have a lower recurrence rate and a better clinical course than patients 
without epilepsy (26, 27). 
The most frequent aberration in gangliogliomas was gain of chromosome 7 detected in 
21% of tumors. Other common gains were on chromosomes 5, 8, 12, and 19. The most 
frequent loss was on 22q in 16% of cases. Other common losses were on Y, 9 and 10. In a 
fraction of tumors, gain of chromosome 7 was found in combination with gains on 5 and/or 8 
and/or 12 and/or 19. By unsupervised cluster analysis, these gangliogliomas with a complete 
gain of chromosome 7 combined with one or more of the other frequent gains were found to 
represent a distinct subgroup (group I). The other group (group II) showed no major recurring 
imbalances except for losses on 9 and 22q, which are not exclusive to group II. Interestingly, 
unsupervised clustering of array CGH data also allowed the molecular subclassification of 
medulloblastomas into two clusters (28), corroborating our data that genomic profiling can 
distinguish genetic subgroups within the same brain tumor entity. Intriguingly, this is not only 
the case for highly malignant CNS tumors, i.e. medulloblastomas, but also for the benign 
gangliogliomas. 
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Since histopathologically the glial cells in gangliogliomas are highly similar to the cells in 
diffuse astrocytomas, the latter tumor type represents an appropriate collective for 
comparison. Thus, the present CGH data were compared with that for diffuse astrocytomas of 
WHO grade II, which we published previously (42, 43). There was no significant difference 
in the chromosomes affected by imbalances except for a chromosome 5 gain found 
significantly more frequently in gangliogliomas. Interestingly, by unsupervised cluster 
analysis all but one diffuse astrocytoma form subclusters defined by single regional 
aberrations within group II of gangliogliomas showing no concordant pattern of genomic 
imbalances. This finding suggests that the ganglioglioma cluster defined by combined gains 
of chromosomes 5, 7, 8 and 12 (group I) represents a subgroup that can be genetically 
distinguished from diffuse astrocytomas, although cellular elements in the latter and the glial 
component of gangliogliomas are generally not distinguishable with respect to their cyto- and 
histopathological characteristics. Similarly, for different astrocytic and oligodendroglial tumor 
entities of WHO grade II to IV, Roerig et al. (35) could show that high-resolution genetic 
profiling allows a distinction between most tumors paralleling the histological classification. 
Array-CGH analysis of gangliogliomas also allowed to identify and fine map several 
imbalances of small chromosomal regions. The most circumscribed aberration was a terminal 
subtelomeric gain on 3p involving 3p26.2-p26.3. Three genes that are preferentially expressed 
in the brain, i.e. CHL1, CNTN6 and CNTN4, are located in this region. CNTN6 and CNTN4
belong to the gene family of contactins, which act as ligands and activators of notch and are 
involved in oligodendrocyte maturation (15) and neurite outgrowth (47). Amplification and 
overexpression of another family member, CNTN2, was reported in individual malignant 
gliomas, and a reduced migration of glioma cells was found when blocking contactin 2 
function (34). CHL1 coding for the neural cell adhesion molecule L1-like protein is detectable 
in neurons, astrocytes, oligodendrocyte precursors and Schwann cells of the mouse and rat
and promotes neurite outgrowth (14). In addition, there is evidence that members of the L1 
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gene family play a role in the adhesion and migration of glioma cells and participate in tumor 
invasion along neuronal fibers (17). Therefore, CNTN6, CNTN4 and CHL1 represent 
interesting target proto-oncogenes in glial tumors. However, it remains to be shown whether 
they are of specific importance in the tumorigenesis of gangliogliomas.
Interphase-FISH experiments to ganglioglioma sections allowed investigations on a 
cellular level. With this approach we wanted to address the question, which of the two cellular 
components of gangliogliomas carry genetic aberrations. In one ganglioglioma, the 
imbalances detected by array-CGH were confirmed and could be localized to a subpopulation 
of glial cells, while no dysplastic neuronal cells carried the aberrations analyzed. These data 
represent genetic evidence, which corroborates histopathological data suggesting that the glial 
cells represent the neoplastic component in gangliogliomas, whereas there were no evident 
signs for neoplasia of the neuronal cells (3, 21, 45). This hypothesis was further supported by 
the finding that a TSC2 sequence alteration detected in a ganglioglioma was restricted to its 
glial cell component (5).
One of the aims of genomic profiling is to set the stage for an individualized medicine 
based on the identification of tumors, which will have a different biological behavior than 
expected from histopathological evaluation. In our series, we had the chance to investigate 
two gangliogliomas (WHO grade I), for which the rare event of tumor recurrence and 
malignant progression to anaplastic ganglioglioma (WHO grade III) was observed. By array-
CGH analysis, the anaplastic recurrences showed genetic aberrations commonly associated 
with malignant gliomas, including amplifications of the oncogenes PDGFRA and CDK4 or 
pronounced losses of the tumor suppressor genes CDKN2A/B and DMBT1 (33). In the array 
CGH profiles of the primary gangliogliomas, the CDK4 amplification was detectable as a 
distinct CDK4 gain in one tumor and the clones containing the CDKN2A/B and DMBT1 genes 
both showed signal ratios indicating a slight loss in the other case. These aberrations, i.e. 
circumscribed CDK4 gain and combined CDKN2A/B and DMBT1 loss, were not found in any 
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of the other gangliogliomas of the present series. In addition, both tumors did not show the 
ganglioglioma typical pattern of genomic imbalances found in cluster group I. Thus, a genetic 
signature different from other gangliogliomas, which have the same histopathological 
features, pointing toward malignant progression is seen in these two cases with malignant 
recurrences. 
These findings were corroborated by data from interphase-FISH. While the CDK4
amplification (copy number higher than 20) was found in all cells of the anaplastic 
ganglioglioma, an increased copy number of CDK4 (3 to 6 copies) was detectable in over 
30% of cells of the primary ganglioglioma. Only 30% of cells showed normal diploid signals. 
The other anaplastic ganglioglioma was found to have a tri- to tetraploid background, i.e. 
three and four copies of control clones, but only one or two copies of clones containing 
CDKN2A/B and DMBT1 in over 70% of cells. The same signal constellation resulting in a 
relative loss of CDKN2A/B and DMBT1 was found in over 50% of cells of the primary 
ganglioglioma, whereas only around 25% of cells showed a normal diploid pattern. Thus, 
interphase-FISH confirms that there are genetic signs indicating tumor evolution towards 
higher malignancy in both gangliogliomas.
In summary, our study provides the first comprehensive overview of genomic alterations 
in a large series of gangliogliomas. We found that two-thirds of cases of this generally benign 
tumor type carried genomic imbalances. One cluster group was identified to be defined by a 
complete gain of chromosome 7 and additional gains of chromosomes 5, 8, 12 or 19, and to 
have a distinct genetic signature compared to diffuse astrocytomas of WHO grade II. A 
subpopulation of glial cells and not the dysplastic neuronal cells were found to harbor the 
chromosomal imbalances. Furthermore, the present data demonstrate the potential of array-
CGH to detect early aberrations in evolving tumors even if they are just present in a 
subpopulation of cells. Therefore, one should consider using array-CGH as an additional 
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diagnostic tool to assess biological tumor behavior and assist in personalizing therapeutic 
strategies even in low-grade tumors.
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Case 
no
Age at 
operation
(years)
Sex
Long 
standing 
epilepsy
CD34 
status CGH loss CGH gain
1 32 M + + - Xp21-q27
2 34 F + +++ 22q -
3 20 F + +++ - 5, 7, 19, 20
4 29 F + +++ - -
5 21 F + +++ - 21q
6 9 F + +++ - -
7 31 F + ++ 5q31-q35, 20 -
8 28 M - +++ 9, 21q, 22q -
9 27 F + +++ - -
10 17 M + +++ 17q24-q25, 22q 7, 8
11 37 M + ++ - 9q32-q34
12 46 M + +++ - -
13 9 M + ++ - -
14 17 F + ++ 10q22-q26, 13q 7, 8, 12
15 16 M + + 15q, 16, 22q 4, 5, 7, 8, 13q, 17, 19, 20, X, Y
16 55 F + ++ - -
17 37 F + ++ - 2, 3, 4, 5
18 20 F + ++ 10q25-q26, 14q24-q32, 16, 18q22-q23, 22q -
19 21 F + ++ 12q23-q24.3 -
20 31 F + +++ 9 7, 8
21 22 F + +++ 9, 16 -
22 23 M + +++ - 5, 7
23 36 F + ++ 22q 5, 7, 8, 12p13-q21
24 22 M + ++ 9q34 -
25 38 F + +++ - -
26 30 M + ++ 18, Yq -
27 54 M + ++ - -
28 23 F + ++ - 9q, 16, 17, 20q
29 39 M + +++ - -
30 48 M + ++ Y 1p12-p13
31 8 M + ++ - -
32 64 F + ++ - -
33 7 F + ++ 11p15 -
34 2 M + + - -
35 16 F + +++ - -
36 2 F - +++ 18, 19, 20q, 21q -
37 27 F + n.d. - -
38 2 F + n.d. - -
39 24 F + n.d. - 8
40 3 M + n.d. 20q X
41 56 F + n.d. - -
42 32 M + +++ - -
43 14 M + +++ 1p, 21q22.11-q22.3 -
44 44 M + + 17p 3p26.2-p26.3
45 9 M - + - 6,10
46 41 M + +++ 9, 13q, 22q -
47 34 F - ++ - 14q32.13-q32.2
48 40 M + ++ - -
49 14 F + + - -
50 31 M + ++ 16, 17, 19, 22q 5, 6, 7, 8, 13q, Y
51 20 M + +++ - -
52 32 M + ++ 22q 5, 7, 8, 11, 12, 15q, 17, 19, 20, 21q, X
53 10 M - +++ 1, 2, 3, 4, 8, 9, 11, 13q, 14q, 17, 22q, Y 5, 6, 7, 10, 12, 15q, 16, 18, 19, 20, 21q, X
54 40 M + +++ 10q22.3-q25.3 5
55 17 M + +++ - -
56 18 M - ++ - 5, 7, 11, 12, 21q
57 38 M - ++ Y -
58 12 M + +++ 2 7, 12, 18, 19, 21q, X, Y
59 54 M - + 10, 18 7, 19
60 60 M - +++ - 12q13.3-q14.1
61 60 M - +++ 10q21.1-q26.3, 13q, 15q11.2-q22.2 -
Table 1. Clinical, histopathologic and CGH (chromosomal (cases 1-41) or array-based (cases 
42-61)) data in 61 gangliogliomas (WHO grade I). Abbreviations: No = number. M = male; 
F = female. CD34 status: + = weak; ++ = moderate; +++ = strong; n.d. = not determined. 
CGH = comparative genomic hybridization.
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FIGURE LEGENDS
Figure 1. Summary of imbalances detected by CGH analysis of 61 gangliogliomas (WHO 
grade I). Alterations found by chromosomal CGH are depicted as continuous lines, array-
CGH findings are shown as dashed lines. Lines to the right of each chromosome ideogram 
indicate gains, lines to the left of an ideogram represent losses. 
Figure 2. Array-CGH profiles of 10 selected gangliogliomas (WHO grade I). Midpoints of all 
clones are plotted in genomic order from 1p to Yq on the x-axis against their normalized log2
test to reference ratio on the y-axis. Vertical bars indicate clones belonging to the same 
chromosome. The following tumors are shown: A: 52, B: 53, C: 56, D: 50, E: 58, F: 59, G:
54, H: 44, I: 43, J: 45. Note that tumor profiles shown in A-F show gains of chromosome 7 
in combination with gains of chromosomes 5, 8, 12 and/or 19 (Table 1). 
Figure 3. Molecular subclassification of gangliogliomas (WHO grade I) by their genomic 
signature and comparison of genetic profiles in gangliogliomas and diffuse astrocytomas 
(WHO grade II). A: Unsupervised cluster analysis of the gangliogliomas showing imbalances 
in CGH analysis (40 of 61 cases). A separation of cases into two major groups is apparent, 
with gains of the whole chromosome 7 being the defining feature of group I (coded yellow). 
Group II (coded blue) does not exhibit major recurring imbalances, with the exception of 
losses on chromosomes 9 and 22, which are, however, not exclusive to the group. 
Interestingly, gain of chromosome 7 appears to be related to a variety of other chromosomal 
gains (e.g. of 5, 8, 12, 19), which can also be found in one highly aberrant case not assigned to 
the two main clusters (coded magenta). B: Histograms comparing the frequency of genomic 
gains (green bars showing upwards) and losses (red bars showing downwards) in 61 
gangliogliomas of WHO grade I (top) and 19 diffuse astrocytomas of WHO grade II (bottom). 
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While mostly the same chromosomes are affected in both tumor entities, the majority of 
imbalances involve whole chromosomes in gangliogliomas versus parts of chromosomes in 
diffuse astrocytomas. Gain of chromosome 5 was the only imbalance found significantly more 
frequently in gangliogliomas. C: Unsupervised cluster analysis of 40 gangliogliomas of WHO 
grade I (coded light blue) and 14 diffuse astrocytomas of WHO grade II (coded pink). While a 
subgroup of gangliogliomas largely corresponding to ganglioglioma cluster group I (compare 
Figure 3A) exhibits a concordant pattern of genomic imbalances, the diffuse astrocytomas 
form small subclusters defined by single regional aberrations (e.g. gains on 7q) within 
ganglioglioma cluster group II (compare Figure 3A).
Figure 4. Analysis of tumor DNA by array-CGH and tissue sections by interphase-FISH. A:
Array-CGH profile (left), interphase-FISH analysis (center), and hematoxylin-eosin-staining 
(right, x40) of ganglioglioma no. 46 exhibiting the typical composition of dysplastic neuronal 
and astroglial elements; note the large dysplastic, occasionally binucleated neuronal cells 
(right, black arrows). The array-CGH profile showed losses of chromosomes 9, 13q, and 22q 
(left). By interphase-FISH, losses of clones on 9 (green arrow in array-CGH profile) and on 
22q (not shown) were verified and the cell component harboring the imbalances was 
identified. Interphase-FISH showed only one signal for clone RP11-392G7 (9q22.32) in 52% 
of glial cells corresponding to a deletion of one allele, but two signals in all neuronal cells 
indicating a normal diploid pattern (center). For clone CTA-229A8 (22q13), one signal was 
found in 38% of glial cells, whereas all neuronal cells showed two signals (data not shown). 
Thus, the imbalances were only detected in a subpopulation of glial and not in neuronal cells.
B: Array-CGH and interphase-FISH analysis of ganglioglioma no. 60 (WHO grade I, upper 
panels) recurring as an anaplastic ganglioglioma (WHO grade III, lower panels) in the same 
patient. In the anaplastic ganglioglioma, array-CGH detected amplifications of clones 
containing the oncogenes PDGFRA (RP11-231C18, 4q12, green arrow) and CDK4 (RP11-
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571M6, 12q14.1, red arrow). By interphase-FISH, more than 20 copies were found for both 
clones in all tumor cells, whereas a control probe (CEN9) was present in up to 4 copies 
corresponding to a near tetraploid karyotype. In the ganglioglioma, array-CGH detected no 
alteration of RP11-231C18 (PDGFRA), while RP11-571M6 (CDK4) showed a subtle gain at 
12q14.1 not identified in any other ganglioglioma. By interphase-FISH, over 30% of cells 
showed more than two signals for RP11-571M6 (CDK4), whereas only 30% of cells had a 
normal diploid pattern (i.e. two signals for all probes used). C: Array-CGH and interphase-
FISH analysis of ganglioglioma no. 61 (WHO grade I, upper panels) recurring as an 
anaplastic ganglioglioma (WHO grade III, lower panels) in the same patient. In the anaplastic 
ganglioglioma, array-CGH identified prominent losses for clones RP11-149I2 (CDKN2A/B, 
9p21.3) and RP11-481L19 (DMBT1, 10q26.13). By interphase-FISH, a pattern of three to 
four signals for control probes and one to two signals for RP11-149I2 (CDKN2A/B) and 
RP11-481L19 (DMBT1) were found in over 70% of cells, corresponding to a relative loss of 
the clones containing these tumor suppressor genes. In the ganglioglioma, the same clones 
showed a diminished ratio by array-CGH making this the only ganglioglioma with combined 
CDKN2A/B and DMBT1 losses. Interphase-FISH showed that on a cellular level the 
alterations were relative losses (one to two signals) compared to control probes present in 
three to four signals (near tri- to tetraploid karyotype) in around 50% of cells.
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Summary of imbalances detected by CGH analysis of 61 gangliogliomas. Alterations found 
by chromosomal CGH are depicted as continuous lines, array-CGH findings are shown as 
dashed lines. Lines to the right of each chromosome ideogram indicate gains, lines to the 
left of an ideogram represent losses. 
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Array-CGH profiles of 10 selected gangliogliomas. Midpoints of all clones are plotted in 
genomic order from 1p to Yq on the x-axis against their normalized log2 test to reference 
ratio on the y-axis. Vertical bars indicate clones belonging to the same chromosome. The 
following tumors are shown: A: 52, B: 53, C: 56, D: 50, E: 58, F: 59, G: 54, H: 44, I: 43, J: 
45. Note that tumors A-F carry gains of chromosome 7 in combination with gains of 
chromosomes 5, 8, 12 and/or 19 (Table 1). 
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Molecular subclassification of gangliogliomas by their genomic signature and comparison 
of genetic profiles in gangliogliomas and diffuse astrocytomas (WHO grade II). A: 
Unsupervised cluster analysis of the gangliogliomas showing imbalances in CGH analysis 
(40 of 61 cases). A separation of cases into two major groups is apparent, with gains of 
the whole chromosome 7 being the defining feature of group I (coded yellow). Group II 
(coded blue) does not exhibit major recurring imbalances, with the exception of losses on 
chromosomes 9 and 22, which are, however, not exclusive to the group. Interestingly, 
gain of chromosome 7 appears to be related to a variety of other chromosomal gains (e.g. 
of 5, 8, 12, 19), which can also be found in one highly aberrant case not assigned to the 
two main clusters (coded magenta). B: Histograms comparing the frequency of genomic 
gains (green bars showing upwards) and losses (red bars showing downwards) in 61 
gangliogliomas (top) and 19 diffuse astrocytomas of WHO grade II (bottom). While 
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mostly the same chromosomes are affected in both tumor entities, the majority of 
imbalances involve whole chromosomes in gangliogliomas versus parts of chromosomes 
in diffuse astrocytomas. Gain of chromosome 5 was the only imbalance found 
significantly more frequently in gangliogliomas. C: Unsupervised cluster analysis of 40 
gangliogliomas (coded light blue) and 14 diffuse astrocytomas of WHO grade II (coded 
pink). While a subgroup of gangliogliomas largely corresponding to ganglioglioma cluster 
group I (compare Figure 3A) exhibits a concordant pattern of genomic imbalances, the 
diffuse astrocytomas form small subclusters defined by single regional aberrations (e.g. 
gains on 7q) within ganglioglioma cluster group II (compare Figure 3A). 
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Analysis of tumor DNA by array-CGH and tissue sections by interphase-FISH. A: Array-
CGH profile (left), interphase-FISH analysis (center), and hematoxylin-eosin-staining 
(right, x40) of ganglioglioma no. 46 exhibiting the typical composition of dysplastic 
neuronal and astroglial elements; note the large dysplastic, occasionally binucleated 
neuronal cells (right, black arrows). The array-CGH profile showed losses of 
chromosomes 9, 13q, and 22q (left). By interphase-FISH, losses of clones on 9 (green 
arrow in array-CGH profile) and on 22q (not shown) were verified and the cell component 
harboring the imbalances was identified. Interphase-FISH showed only one signal for 
clone RP11-392G7 (9q22.32) in 52% of glial cells corresponding to a deletion of one 
allele, but two signals in all neuronal cells indicating a normal diploid pattern (center). 
For clone CTA-229A8 (22q13), one signal was found in 38% of glial cells, whereas all 
neuronal cells showed two signals (data not shown). Thus, the imbalances were only 
detected in a subpopulation of glial and not in neuronal cells. B: Array-CGH and 
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interphase-FISH analysis of ganglioglioma no. 60 (WHO grade I, upper panels) recurring 
as an anaplastic ganglioglioma (WHO grade III, lower panels) in the same patient. In the 
anaplastic ganglioglioma, array-CGH detected amplifications of clones containing the 
oncogenes PDGFRA (RP11-231C18, 4q12, green arrow) and CDK4 (RP11-571M6, 12q14.1, 
red arrow). By interphase-FISH, more than 20 copies were found for both clones in all 
tumor cells, whereas a control probe (CEN9) was present in up to 4 copies corresponding 
to a near tetraploid karyotype. In the ganglioglioma, array-CGH detected no alteration of 
RP11-231C18 (PDGFRA), while RP11-571M6 (CDK4) showed a subtle gain at 12q14.1 not 
identified in any other ganglioglioma. By interphase-FISH, over 30% of cells showed 
more than two signals for RP11-571M6 (CDK4), whereas only 30% of cells had a normal 
diploid pattern (i.e. two signals for all probes used). C: Array-CGH and interphase-FISH 
analysis of ganglioglioma no. 61 (WHO grade I, upper panels) recurring as an anaplastic 
ganglioglioma (WHO grade III, lower panels) in the same patient. In the anaplastic 
ganglioglioma, array-CGH identified prominent losses for clones RP11-149I2 (CDKN2A/B, 
9p21.3) and RP11-481L19 (DMBT1, 10q26.13). By interphase-FISH, a pattern of three to 
four signals for control probes and one to two signals for RP11-149I2 (CDKN2A/B) and 
RP11-481L19 (DMBT1) were found in over 70% of cells, corresponding to a relative loss 
of the clones containing these tumor suppressor genes. In the ganglioglioma, the same 
clones showed a diminished ratio by array-CGH making this the only ganglioglioma with 
combined CDKN2A/B and DMBT1 losses. Interphase-FISH showed that on a cellular level 
the alterations were relative losses (one to two signals) compared to control probes 
present in three to four signals (near tri- to tetraploid karyotype) in around 50% of cells.
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